Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells.

T Ikezoe1, E S Daar, J Hisatake

  • 1Division of Hematology/Oncology, Infectious Disease, Cedars-Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA, USA.

Blood
|November 9, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival.

Oncogenesis·2025
Same author

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

HIV medicine·2018
Same author

Targeting the vulnerability to NAD<sup>+</sup> depletion in B-cell acute lymphoblastic leukemia.

Leukemia·2017
Same author

Integrative analyses of transcriptome sequencing identify novel functional lncRNAs in esophageal squamous cell carcinoma.

Oncogenesis·2017
Same author

Preleukemia: one name, many meanings.

Leukemia·2016
Same author

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.

Leukemia·2016

HIV-1 protease inhibitors enhance all-trans retinoic acid (ATRA) efficacy in myeloid leukemia. This combination therapy shows promise for treating acute promyelocytic leukemia and retinoid-resistant cancers.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • HIV-1 protease inhibitors may affect retinoid activity by inhibiting key cellular proteins.
  • Retinoids, like ATRA, are used in cancer therapy but can face resistance.

Purpose of the Study:

  • To investigate if HIV-1 protease inhibitors can enhance the anti-leukemic effects of ATRA.
  • To explore the potential of combining these agents for treating myeloid leukemia.

Main Methods:

  • Culturing myeloid leukemia cell lines (HL-60, NB4, UF-1) with ATRA alone and with HIV-1 protease inhibitors (indinavir, ritonavir, saquinavir).
  • Assessing cell growth inhibition and differentiation induction via cell surface markers (CD11b, CD66b) and nitroblue tetrazolium reduction.
  • Measuring the expression of the C/EBPepsilon transcription factor.

Related Experiment Videos

Main Results:

  • HIV-1 protease inhibitors significantly enhanced ATRA's ability to inhibit growth and induce differentiation in HL-60 and NB4 cells.
  • The combination therapy also inhibited growth in ATRA-resistant UF-1 cells.
  • Indinavir notably increased ATRA-induced C/EBPepsilon mRNA expression by 9.5-fold.

Conclusions:

  • HIV-1 protease inhibitors potentiate the antiproliferative and differentiation-inducing effects of ATRA on myeloid leukemia cells.
  • This combination strategy may be beneficial as an adjuvant therapy for acute promyelocytic leukemia.
  • The findings suggest potential applications in treating other retinoid-resistant cancers.